Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3459/1/21: Complainant v Napp β€” Invokana webcast advertisement (No breach)

Napp was accused of off-licence renoprotection claims and missing renal dosing/adult-only info in an Invokana webcast ad. Panel…

8 Mar 2026

LEO Pharma: Protopic β€˜At a glance’ HCP webpage – misleading maintenance-therapy graph and sun-exposure imagery (AUTH/3501/4/21)

LEO’s Protopic HCP webpage breached the Code for an image implying no need for sun precautions and for…

8 Mar 2026

Gilead (HIV.eu): HCP website content and PI links accessible to the public due to broken patient-site routing

Gilead’s HIV.eu HCP site briefly remained accessible after β€œvisit patient site” failed. Panel found promotional HCP content likely…

8 Mar 2026

Teva: P3 Pharmacy interview article deemed promotionalβ€”missing PI, AE statement and black triangle; Copaxone indication overstated

A P3 Pharmacy interview featuring Teva content was ruled promotional. The article lacked PI, AE reporting statement, certification…

8 Mar 2026

Wyeth v Roche and Chugai: press statements about unlicensed Actemra (tocilizumab) found misleading and disparaging

Wyeth challenged Roche/Chugai media claims about unlicensed tocilizumab. The Panel ruled several claims misleading, unsubstantiated and exaggerated, and…

8 Mar 2026

AUTH/2183/11/08: Merz Pharma v Allergan – misleading potency comparison for Botox vs Xeomin

Allergan materials and representative messaging suggested Xeomin was ~70% as potent as Botox based on animal assay data.…

8 Mar 2026

Takeda v Merck Sharp & Dohme: Cozaar ad criticised for misleading meta-analysis presentation and selective Cochrane quoting

MSD’s Cozaar ad claimed losartan was β€œas effective as other leading AIIAs” and quoted a Cochrane review. PMCPA…

8 Mar 2026

AUTH/2308/4/10: Media/Director v Norgine – undisclosed company role behind public letter on generic substitution

Norgine funded and coordinated a PR-led campaign that resulted in a Times letter opposing automatic generic substitution, but…

8 Mar 2026

Merz: employee delivered Bocouture from Northern Ireland to Republic of Ireland (unlicensed) after shipping error (AUTH/3264/10/19)

A Merz employee personally delivered Bocouture into the Republic of Ireland where it was unlicensed, to fix a…

8 Mar 2026

AUTH/2457/11/11: General Practitioner v Teva β€” Qvar BMJ ad challenged on missing statistical detail (No breach)

A GP challenged a BMJ ad for Qvar alleging omission of confidence intervals/p values made a comparative claim…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training